Mylan, Pfizer settle epinephrine auto-injector patent litigation with Sanofi
Mylan and Pfizer have agreed to settle their patent litigation with Sanofi-Aventis over pre-filled injections designed to treat severe allergic reactions.
Meridian Medical Technologies, a Pfizer subsidiary, has signed a settlement agreement with Intelliject and Sanofi that will resolve pending patent litigation related to Intelliject's NDA for its epinephrine auto-injector (e-cue).
Under the settlement agreement, Intelliject and Sanofi may launch e-cue no earlier than 15 November 2012, subject to receipt of final approval from the FDA.
Meridian manufactures e-cue and Mylan Specialty commercializes the product in the US.
Mylan CEO Heather Bresch said the EpiPen Auto-Injector will continue to be a market leader, given the proud, 20-year heritage of this important treatment for anaphylaxis.
CommentsPost a comment
Comments may be moderated for spam, obscenities or defamation.
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs